Overview

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

Status:
Terminated

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

The objectives of this study are to evaluate the efficacy and safety of the Zevalin regimen compared to Zevalin and motexafin gadolinium in patients with rituximab-refractory, low-grade or follicular Non-Hodgkin's Lymphoma (NHL). Effectiveness of the experimental regimen assessed by complete response rate within 6 months of study entry (primary endpoint), complete response rate within 3 months of study entry, and overall response rate within 6 month of study entry.

Phase:

Phase 2

Details

Lead Sponsor:

Spectrum Pharmaceuticals, Inc

Treatments:

Antibodies, Monoclonal
Motexafin gadolinium
Rituximab